Federal Register / Vol. 70, No.

165 / Friday, August 26, 2005 / Notices 50377

TABLE 1.
21 CFR Section Affected,
Sponsor NADA Number, Product (Drug) (Sponsor Drug Labeler
Code)

Abbott Laboratories, North Chicago, IL NADA 99–568, FURANACE Caps (nifurpirinol) 529.1526 (000074)
60064

Biocraft Laboratories, Inc., 92 Route 46, NADA 140–889, DERM–OTIC Ointment (neomycin sulfate, nys- 524.1600a (000332)
Elmwood Park, NJ 07407 tatin, thiostrepton, triamcinolone acetonide)

First Priority, Inc., 1585 Todd Farm Dr., NADA 48–646, THERAZONE Injection (phenylbutazone) 522.1720 (058829)
Elgin, IL 60123

Happy Jack, Inc., Snow Hill, NC 28580 NADA 121–556, Selenium Sulfide Suspension (selenium disulfide) 524.2101 (023851)
NADA 121–723, Nitrofurazone Dressing 524.1580b (023851)
NADA 125–137, FILARICIDE Capsules (diethylcarbamazine cit- 520.622d (023851)
rate)

IMPAX Laboratories, Inc., 30831 Huntwood NADA 92–151, N-Butyl Chloride Canine Worming Caps 520.260 (000115)
Ave., Hayward, CA 94544
NADA 65–065, Tetracycline HCl Caps 520.2345a (000115)
NADA 138–900, Dichlorophene/Toluene 520.580 (000115)

Jorgensen Laboratories, Inc., 1450 North NADA 10–481, SUREJETS (salacylic acid) 529.2090 (048087)
Van Buren Ave., Loveland, CO 80538

Pliva d.d., Ulica grada Vukovara 49, 10000 ANADA, 200–232, GEOMYCIN 200 Injection (oxytetracycline) 522.1660a (011722)
Zagreb, Croatia

Purina Mills, Inc., P.O. Box 66812, St. Louis, NADA 65–113 AUREO Sulfa Soluble Powder (chlortetracycline/ N/A (017800)
MO 63166-6812 sulfamethazine)

Roche Vitamins, Inc., 45 Waterview Blvd., NADA 140–848, VETEEZE Injection (diazepam) 522.575 (063238)
Parsippany, NJ 07054–1298

Teva Pharmaceuticals USA, 650 Cathill Rd., NADA 131–806, Furosemide Tablets 520.1010 (000093)
Sellersville, PA 18960

Virbac AH, Inc., 3200 Meacham Blvd., Ft. NADA 10–886, Purina Liquid Wormer (piperazine citrate) N/A (051311)
Worth, TX 76137

Wyeth Laboratories, Division of American NADA 10–782, SPARINE Injection (promazine) 522.1962 (000008)
Home Products Corp., P.O. Box 8299,
Philadelphia, PA 19101
NADA 55–008, BICILLIN Fortified (penicillin G benzathine and 522.1696a (000008)
penicillin G procaine)

Therefore, under authority delegated
to the Commissioner of Food and Drugs
(21 CFR 5.10), redelegated to the Center
for Veterinary Medicine (21 CFR 5.84),
and in accordance with § 514.115
Withdrawal of approval of applications
(21 CFR 514.115), notice is given that
approval of NADAs 10–481, 10–782,
10–886, 48–646, 55–008, 65–065, 65–
113, 99–568, 121–556, 121–723, 125–
137, 131–806, 138–900, 140–848, 140–
889, and ANADA 200–232, and all
supplements and amendments thereto,
is hereby withdrawn, effective
September 6, 2005.
In a final rule published elsewhere in
this issue of the Federal Register, FDA
is amending the animal drug regulations
to reflect the withdrawal of approval of
these NADAs.
Dated: July 5, 2005.
Linda Tollefson,
Acting Director, Center for Veterinary
Medicine.
[FR Doc. 05–16994 Filed 8–25–05; 8:45 am]
BILLING CODE 4160–01–S
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
National Institutes of Health
Notice of Establishment
Pursuant to the Federal Advisory
Committee Act, as amended (5 U.S.C.
Appendix 2), the Director, National
Institutes of Health (NIH), announces
the establishment of the National
Commission on Digestive Diseases
(Commission).
This Commission shall conduct an
overview of the state-of-the-science in
the field of digestive diseases research
and develop a long-range plan for
digestive diseases research consistent
with the research mission of NIH. The
overall plan will focus on the goal of
improving the health of the nation
through digestive diseases research and
will include specific objectives and
goals and a recommended time line for
their implementation.
Recommendations shall be made to the
Director, NIH and to Congress.
The Commission shall be composed
of 16 members appointed by the
Director, NIH and 18 nonvoting ex
officio members. Of the appointed
members, who shall have a broad
diversity of scientific and professional
experience, 12 shall be knowledgeable
about digestive diseases as members of
academic or medical research and
practice communities involved in
digestive diseases research, including

VerDate jul<14>2003 16:18 Aug 25, 2005 Jkt 205001 PO 00000 Frm 00087 Fmt 4703 Sfmt 4703 E:\FR\FM\26AUN1.SGM 26AUN1
 50378 Federal Register / Vol. 70, No. 165 / Friday, August 26, 2005 / Notices
individuals in allied health specialties
relevant to digestive diseases research.
Four members shall be appointed who
have close personal or family
experience with digestive diseases or
experience with patient-oriented
organizations in digestive diseases.
Unless renewed by appropriate action
prior to its expiration, the Charter for
the National Commission on Digestive
Diseases will expire two years from the
date of establishment.
Dated: August 16, 2005.
Elias A. Zerhouni,
Director, National Institutes of Health.
[FR Doc. 05–17012 Filed 8–25–05; 8:45 am]
BILLING CODE 4140–01–M
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
National Institutes of Health
Office of the Director, National
Institutes of Health; Notice of Closed
Meeting
Pursuant to section 10(d) of the
Federal Advisory Committee Act, as
amended (5 U.S.C. Appendix 2), notice
is hereby given of a meeting of the
Advisory Committee to the Director,
NIH.
The meeting will be closed to the
public in accordance with the
provisions set forth in sections
552b(c)(4) and 552b(c)(6), Title 5 U.S.C.,
as amended. The grant applications and
the discussions could disclose
confidential trade secrets or commercial
property such as patentable material,
and personal information concerning
individuals associated with the grant
applications, the disclosure of which
would constitute a clearly unwarranted
invasion of personal privacy.
Name of Committee: Advisory Committee
to the Director, NIH.
Date: September 6, 2005.
Time: 11 a.m. to 12 p.m.
Place: National Institutes of Health,
Building 31, 31 Center Drive, Room 5B64,
Bethesda, MD 20892.
Agenda: To review and evaluate grant
applications (Telephone Conference Call).
Contact Person: Shelly Pollard, ACD
Coordinator, National Institutes of Health,
9000 Rockville Pike, Building 31, Room
5B64, Bethesda, MD 20892, 301–496–0959.
Any interested person may file written
comments with the committee by forwarding
the statement to the Contact Person listed on
this notice. The statement should include the
name, address, telephone number and when
applicable, the business or professional
affiliation of the interested person.
VerDate jul<14>2003 16:18 Aug 25, 2005 Jkt 205001
Dated: August 19, 2005.
Anthony M. Coelho, Jr.,
Acting Director, Office of Federal Advisory
Committee Policy.
[FR Doc. 05–17016 Filed 8–25–05; 8:45 am]
BILLING CODE 4140–01–M
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
National Institutes of Health
National Cancer Institute; Notice of
Meeting
Pursuant to section 10(d) of the
Federal Advisory Committee Act, as
amended (5 U.S.C. Appendix 2), notice
is hereby given of the meeting of the
National Cancer Advisory Board.
The meeting will be open to the
public as indicated below, with
attendance limited to space available.
Individuals who plan to attend and
need special assistance, such as sign
language interpretation or other
reasonable accommodations, should
notify the Contact Person listed below
in advance of the meeting.
A portion of the meeting will be
closed to the public in accordance with
the provisions set forth in sections
552b(c)(4), and 552b(c)(6), as amended.
The grant applications and the
discussions could disclose confidential
trade secrets or commercial property
such as patentable material, and
personal information concerning
individuals associated with the grant
applications, the disclosure of which
would constitute a clearly unwarranted
invasion of personal privacy.
Name of Committee: National Cancer
Advisory Board.
Open: September 20, 2005, 8 a.m. to 4:15
p.m.
Agenda: Program reports and
presentations; Business of the Board.
Place: National Cancer Institute, 9000
Rockville Pike, Building 31, C Wing, 6th
Floor, Conference Room 10, Bethesda, MD
20892.
Contact Person: Dr. Paulette S. Gray,
Executive Secretary, National Cancer
Institute, National Institutes of Health, 6116
Executive Boulevard, 8th Floor, Room 8001,
Bethesda, MD 20892–8327, (301) 496–5147.
Name of Committee: National Cancer
Advisory Board.
Closed: September 20, 2005, 4:15 p.m. to
Adjournment.
Agenda: Review of grant applications.
Contact Person: Dr. Paulette S. Gray,
Executive Secretary, National Cancer
Institute, National Institutes of Health, 6116
Executive Boulevard, 8th Floor, Room 8001,
Bethesda, MD 20892–8327, (301) 496–5147.
Name of Committee: National Cancer
Advisory Board.
Open: September 21, 2005, 8 a.m. to 12
p.m.
PO 00000 Frm 00088 Fmt 4703 Sfmt 4703 E:\FR\FM\26AUN1.SGM
Agenda: Program reports and
presentations; Business of the Board.
Contact Person: Dr. Paulette S. Gray,
Executive Secretary, National Cancer
Institute, National Institutes of Health, 6116
Executive Boulevard, 8th Floor, Room 8001,
Bethesda, MD 20892–8327, (301) 496–5147.
Any interested person may file written
comments with the committee by forwarding
the statement to the Contact person listed on
this notice. The statement should include the
name, address, telephone number and when
applicable, the business or professional
affiliation of the interested person.
Information is also available on the
Institute’s/Center’s Home page:
deainfo.nci.nih.gov/advisory/ncab.htm,
where an agenda and any additional
information for the meeting will be posted
when available.
(Catalogue of Federal Domestic Assistance
Program Nos. 93.392, Cancer Construction;
93.393, Cancer Cause and Prevention
Research; 93.394, Cancer Detection and
Diagnosis Research; 93.395, Cancer
Treatment Research; 93.396, Cancer Biology
Research; 93.397, Cancer Centers Support;
93.398, Cancer Research Manpower; 93.399,
Cancer Control, National Institutes of Health,
HHS.)
Dated: August 18, 2005.
Anthony M. Coelho, Jr.,
Acting Director, Office of Federal Advisory
Committee Policy.
[FR Doc. 05–17011 Filed 8–25–05; 8:45 am]
BILLING CODE 4140–01–M
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
National institutes of Health
National Center for Complementary &
Alternative Medicine; Notice of Closed
Meeting
Pursuant to section 10(d) of the
Federal Advisory Committee Act, as
amended (5 U.S.C. Appendix 2), notice
is hereby given of the following
meeting.
The meeting will be closed to the
public in accordance with the
provisions set forth in sections
552b(c)(4) and 552b(c)(6), Title 5 U.S.C.,
as amended. The grant applications and
the discussions could disclose
confidential trade secrets or commercial
properly such as patentable material,
and personal information concerning
individuals associated with the grant
applications, the disclosure of which
would constitute a clearly unwarranted
invasion of personal privacy.
Name of Committee: National Center for
Complementary and Alternative Medicine
Special Emphasis Panel Basic Science.
Date: October 17–18, 2005.
Time: 8 a.m. to 3 p.m.
Agenda: To review and evaluate grant
applications.
26AUN1